198 related articles for article (PubMed ID: 29312603)
1. Intratumoral heterogeneity and
Juratli TA; Thiede C; Koerner MVA; Tummala SS; Daubner D; Shankar GM; Williams EA; Martinez-Lage M; Soucek S; Robel K; Penson T; Krause M; Appold S; Meinhardt M; Pinzer T; Miller JJ; Krex D; Ely HA; Silverman IM; Christiansen J; Schackert G; Wakimoto H; Kirsch M; Brastianos PK; Cahill DP
Oncotarget; 2017 Dec; 8(65):109228-109237. PubMed ID: 29312603
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
3. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
4. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas.
Won SY; Lee JH; Lee N; Park YW; Ahn SS; Kim J; Chang JH; Kim SH; Lee SK
PLoS One; 2022; 17(10):e0276342. PubMed ID: 36264940
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
[TBL] [Abstract][Full Text] [Related]
7. Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas.
Shin I; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
J Neuroradiol; 2022 Jan; 49(1):59-65. PubMed ID: 33716047
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
10. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Juratli TA; McCabe D; Nayyar N; Williams EA; Silverman IM; Tummala SS; Fink AL; Baig A; Martinez-Lage M; Selig MK; Bihun IV; Shankar GM; Penson T; Lastrapes M; Daubner D; Meinhardt M; Hennig S; Kaplan AB; Fujio S; Kuter BM; Bertalan MS; Miller JJ; Batten JM; Ely HA; Christiansen J; Baretton GB; Stemmer-Rachamimov AO; Santagata S; Rivera MN; Barker FG; Schackert G; Wakimoto H; Iafrate AJ; Carter SL; Cahill DP; Brastianos PK
Acta Neuropathol; 2018 Nov; 136(5):779-792. PubMed ID: 30123936
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
13.
Kikuchi Z; Shibahara I; Yamaki T; Yoshioka E; Shofuda T; Ohe R; Matsuda KI; Saito R; Kanamori M; Kanemura Y; Kumabe T; Tominaga T; Sonoda Y
Neurooncol Adv; 2020; 2(1):vdaa114. PubMed ID: 33134923
[TBL] [Abstract][Full Text] [Related]
14. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
16. H3K27M and
Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205
[TBL] [Abstract][Full Text] [Related]
17. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
18. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
20. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
